{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-044357","form_type":"8-K","ticker":"INFU","cik":"0001337013","company_name":"InfuSystem Holdings, Inc","filed_at":"2025-10-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.183525+00:00","generated_at":"2026-05-17T04:33:33.695006+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"InfuSystem updates TTM revenue to ~$140M, adj EBITDA ~$30M; net leverage 0.86x","bullets":["TTM 6/30/25 net revenue ~$140M, up from $134.9M in FY2024; adjusted EBITDA ~$30M vs. $25.3M.","Net leverage 0.86x, debt/equity 0.85x, total available liquidity $49.1M.","Share repurchase: $7.6M bought under $20M program through June 30, 2025.","Patient Services gross margin 64.5% TTM; Device Solutions gross margin 39.6% TTM.","Management estimates FY2025 revenue growth 6-8% and adjusted EBITDA margin >20%."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-044357","json":"https://secwatch.observer/filing/0001628280-25-044357.json","markdown":"https://secwatch.observer/filing/0001628280-25-044357.md","text":"https://secwatch.observer/filing/0001628280-25-044357.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1337013/000162828025044357/0001628280-25-044357-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1337013/000162828025044357/infu-20251006.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:33:33.695006+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}